Prion diseases are caused by a conformational modification of the cellular prion protein (PrP (C) ) into disease-specific forms, termed PrP (Sc) , that have the ability to interact with PrP (C) promoting its conversion to PrP (Sc) . In vitro studies demonstrated that anti-PrP antibodies inhibit this process. In particular, the single chain variable fragment D18 antibody (scFvD18) showed high efficiency in curing chronically prion-infected cells. This molecule binds the PrP (C) region involved in the interaction with PrP (Sc) thus halting further prion formation. These findings prompted us to test the efficiency of scFvD18 in vivo. A recombinant Adeno-Associated Viral vector serotype 9 was used to deliver scFvD18 to the brain of mice that were subsequently infected by intraperitoneal route with the mouse-adapted scrapie strain RML. We found that the treatment was safe, prolonged the incubation time of scrapie-infected animals and decreased the burden of total proteinase-resistant PrP (Sc) in the brain, suggesting that scFvD18 interferes with prion replication in vivo. This approach is relevant for designing new therapeutic strategies for prion diseases and other disorders characterized by protein misfolding.

Brain delivery of AAV9 expressing an anti-PrP monovalent antibody delays prion disease in mice / Moda, F.; Vimercati, C.; Campagnani, I.; Ruggerone, M.; Giaccone, G.; Morbin, M.; Zentilin, L.; Giacca, M.; Zucca, I.; Legname, Giuseppe; Tagliavini, F.. - In: PRION. - ISSN 1933-6896. - 6:4(2012), pp. 383-390. [10.4161/pri.20197]

Brain delivery of AAV9 expressing an anti-PrP monovalent antibody delays prion disease in mice

Legname, Giuseppe;
2012-01-01

Abstract

Prion diseases are caused by a conformational modification of the cellular prion protein (PrP (C) ) into disease-specific forms, termed PrP (Sc) , that have the ability to interact with PrP (C) promoting its conversion to PrP (Sc) . In vitro studies demonstrated that anti-PrP antibodies inhibit this process. In particular, the single chain variable fragment D18 antibody (scFvD18) showed high efficiency in curing chronically prion-infected cells. This molecule binds the PrP (C) region involved in the interaction with PrP (Sc) thus halting further prion formation. These findings prompted us to test the efficiency of scFvD18 in vivo. A recombinant Adeno-Associated Viral vector serotype 9 was used to deliver scFvD18 to the brain of mice that were subsequently infected by intraperitoneal route with the mouse-adapted scrapie strain RML. We found that the treatment was safe, prolonged the incubation time of scrapie-infected animals and decreased the burden of total proteinase-resistant PrP (Sc) in the brain, suggesting that scFvD18 interferes with prion replication in vivo. This approach is relevant for designing new therapeutic strategies for prion diseases and other disorders characterized by protein misfolding.
2012
6
4
383
390
Moda, F.; Vimercati, C.; Campagnani, I.; Ruggerone, M.; Giaccone, G.; Morbin, M.; Zentilin, L.; Giacca, M.; Zucca, I.; Legname, Giuseppe; Tagliavini, F.
File in questo prodotto:
File Dimensione Formato  
Moda_PRION_2012.pdf

non disponibili

Tipologia: Versione Editoriale (PDF)
Licenza: Non specificato
Dimensione 3.54 MB
Formato Adobe PDF
3.54 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11767/17287
Citazioni
  • ???jsp.display-item.citation.pmc??? 13
  • Scopus 23
  • ???jsp.display-item.citation.isi??? 20
social impact